Piper Jaffray Initiates Coverage of Meridian Bioscience with Underweight Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Piper Jaffray today initiated coverage of Meridian Bioscience with an Underweight rating, saying that its nascent molecular diagnostics business faces multiple challenges from competitors.

The investment bank gave Meridian a $14 target price on its stock, and estimated 2011 sales at $159.8 million, resulting in net earnings of $28.5 million, or $.69 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.